CALLE DOCTOR FLEMING, 51 | 28036 MADRID, SPAIN
+34 91 3459395 | +44 (0) 20 3951 8071
info@oxonepi.com

OXON RWE capabilities at ICPE Conference – 23-27 August 2023

ICPE 2023

OXON’s RWE solutions at the 39th International Conference on PharmacoEpidemiology, ICPE 2023.

The Global Home for the Science of Real-World

August 23-27, 2023. | Halifax Convention Centre | Halifax, Nova Scotia, Canada

OXON will be supporting ICPE 2023 as an exhibitor, presenting its expertise in RWE during this virtual and in-person interactional scientific event as well as its new portfolio of services

OXON is pleased to inform you that we will be at the Halifax Convention Centre in Halifax, Canada, exhibiting and presenting at the 39th International Conference on PharmacoEpidemiology.

We invite you to visit us during the conference and find out how best we can support your needs for inspired and proven world-class approaches to global real-world field, secondary data and hybrid studies, in all therapy areas, including orphan conditions, vaccines and pregnancy.

We will be exhibiting at booth #209 looking forward to discussing the extension of services for observational/RW data alongside trials (e.g., external controls groups) and pragmatic trials (of drugs, devices, mobile apps and educational materials) as a result of our 10-year close relationship with Stuart Pocock, Professor of Medical Statistics, London School of Hygiene and Tropical Medicine.

We also have a new partnership with a global company for economic modelling, so the clinical, safety, PRO and healthcare resource use outcomes from the RW studies we conduct can be used for economic modelling and HTA submissions.

Our senior team will demonstrate our cost-effective solutions, services, designs and implementation options to help you optimize your investment in real-world evidence and support you to effectively meet your real-world data requirements for Safety, Market access and Clinical development.

Poster presentation:

  • Poster Session A:  Friday, 25 August 2023
    (26) [364] Effectiveness of additional risk minimisation measures: Improving response rates and validity in surveys

Schedule a Meeting